Dysgeusia News and Research

RSS
Merck secures worldwide rights to vernakalant i.v.

Merck secures worldwide rights to vernakalant i.v.

Roche, Merck sign new non-exclusive agreement for HCV triple combination therapy

Roche, Merck sign new non-exclusive agreement for HCV triple combination therapy

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

The Lancet publishes VIVUS 56-week QNEXA study results in obesity

The Lancet publishes VIVUS 56-week QNEXA study results in obesity

Investigational drug effective for patients with obesity

Investigational drug effective for patients with obesity

Merck enters definitive agreement to acquire Inspire

Merck enters definitive agreement to acquire Inspire

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

Positive results from Meda's Dymista Phase III trial in patients with SAR

Positive results from Meda's Dymista Phase III trial in patients with SAR

Bayer receives FDA approval for Gadavist Injection

Bayer receives FDA approval for Gadavist Injection

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression